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Edited by Lukas HuberAbstract Insulin-like growth factor (IGF-1) plays an important
role in prostate cancer development. Recent studies suggest that
IGF-1 has mitogenic action through epidermal growth factor
receptor (EGFR). However, the mechanism remains largely un-
known. Here, we demonstrated in prostate cancer DU145 cells
that IGF-1 induced EGFR transactivation, leading to ERK acti-
vation. Matrix metalloproteinase-mediated shedding of heparin-
binding EGF is involved in this process. Antioxidants and
catalase inhibited IGF-1-stimulated EGFR phosphorylation,
indicating that H2O2 is required for EGFR activation. However,
exogenous H2O2 did not activate EGFR or IGF-1R in DU145
cells. IGF-1 did not induced production of H2O2 in DU145 cells.
Our results suggest that transactivation of EGFR by IGF-1
requires basal intracellular H2O2 in DU145 cells.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Prostate cancer is one of the most commonly diagnosed
malignant tumors in Western countries. The standard treat-
ment for prostate cancer is androgen ablation. This blocks
the hormonal signaling cascade. In the hormone-responsive
stage, this treatment results in down-regulation of androgen-
responsive genes and leads to cell proliferation inhibition and
apoptosis. Although androgen ablation is initially successful,
tumors eventually overcome androgen blockade and develop
a hormone-refractory phenotype. These cells are highly
responsive to residual circulating androgens, growth factors,
and other cellular regulators. In this respect, the mitogenic ef-
fects of growth factors are of utmost signiﬁcance [1,2]. It has
been demonstrated that stromal prostate tissue supports theAbbreviations: EGF, epithelial growth factor; EGFR, epithelial growth
factor receptor; HB-EGF, heparin-binding EGF; IGF-1, insulin-like
growth factor; IGF-1R, IGF-1 receptor; MAPK, mitogen-activated
protein kinase; MMP, matrix metalloproteinase; NAC, N-acetyl-cyst-
eine; PI3K, phosphatidylinositol 3-kinase
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doi:10.1016/j.febslet.2006.08.068growth of cancer cells predominantly by secreting growth fac-
tors. The insulin-like growth factor 1(IGF-I) is a potent mito-
gen that plays a regulatory role in proliferation of prostate
cancer cells. High serum levels of IGF-I have recently been
shown to be associated with an increased risk for prostate can-
cer [3].
The signaling pathways through which IGF-I promotes
mitogenesis and other responses have been extensively studied
in several experimental systems [4]. IGF-I binds to the IGF-I
receptor (IGF-1R), which is a heterotetrameric transmem-
brane glycoprotein comprising two a subunits and two b sub-
units. The b subunits express intrinsic tyrosine kinase activity,
which is activated upon ligand binding to the a subunits. Tyro-
sine kinase activation results in autophosphorylation of the b
subunits on speciﬁc tyrosine residues. Activated IGF-IR
phosphorylates adaptor proteins, such as SHC (Src homol-
ogy/a-collagen) and IRS-1, which themselves are coupled to
major signaling pathways such as the Ras-Raf-mitogen-acti-
vated protein kinase (MAPK)/ERK and phosphatidylinositol
3-kinase (PI3K)-AKT pathways. The roles played by SHC-
and IRS-dependent pathways in mediating biological re-
sponses to IGF-I appear to be dependent upon the cell context
[5,6].
Recent studies have provided evidence for an involvement of
epithelial growth factor receptor (EGFR) in IGF-I action [7–
13]. Results from these studies suggest that IGF-1 activates
ERK MAPK through EGFR. Little, however, is known about
the mechanism that IGF-1 activates EGFR/ERK cascade. In
COS-7 and HEK-293 cells, IGF-1 transactivates EGFR
through shedding of heparin-binding epithelial growth factor
(HB-EGF) [9,13]. But in normal human mammary epithelial
cells, IGF-1 activates EGFR not through matrix metallopro-
teinase (MMP)-mediated release of HB-EGF [10].
In human prostate cancer cells, blockade of EGFR also sup-
pressed of IGF-1-induced activation of ERK [8], suggesting
that IGF-1 activates ERK via EGFR. However, the mecha-
nisms that are involved in this process are not clear. We found
in human prostate cancer DU145 cells that basal intracellular
H2O2 is required for activation of EGFR by IGF-1.2. Materials and methods
2.1. Reagents
Antibodies against IGF-IR b subunit, pEGFR (Tyr 1173), EGFR,
pERK, ERK2 and Protein A/G PLUS–Agarose beads were from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies againstblished by Elsevier B.V. All rights reserved.
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Cellular Signaling (Beverly, MA). Antibody against phosphotyrosine
(4G10) was from Upstate Biotechnology (Lake Placid, NY). HB-
EGF neutralizing antibody is from R&D (Minneapolis, MN). IGF-
1, EGF, LY294002 and AG1478 were from Sigma (St. Louis, MO).
H2DCF-DA was from Molecular Probes (Eugene, OR) and GM6001
was from Calbiochem (San Diego, CA).2.2. Cell culture
DU145 prostate cells were grown in RPMI medium (Invitrogen)
with 10% heated-inactivated fetal bovine serum, 100 u/ml penicillin,
and 100 lg/ml streptomycin, in 5% CO2 incubator at 37 C.p-AKT
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B2.3. Immunoblotting and immunoprecipitation
Immunoblotting was performed as described previously [14]. For
immunoprecipitation, 500 lg of cellular proteins was incubated with
1 lg of anti-IGF-1Rb antibody at 4 C for 4 h. 30 ll of protein A/G
agarose beads was added and incubated at 4 C overnight. The beads
were washed four times with cold PBS buﬀer. Thirty-six microliters of
SDS sample buﬀer (2·) were added and boiled for 3 min. The immu-
noprecipitates were resolved on SDS–PAGE gel (8%).
2.4. Cell cycle analysis
DU145 cells were made quiescent in serum-free media for 24 h. The
old medium was discarded and fresh serum-free medium containing
IGF-1 was provided with inhibitors. In 24 h, the cells were harvested
and ﬁxed with 70% ice-cold ethanol, followed by the incubation in
freshly prepared nuclei staining buﬀer (0.1% Triton X-100 in PBS,
200 lg/ml RNase, and 20 lg/ml propidium iodide (PI)) at 37 C for
15 min. Cell-cycle histograms were generated by ﬂuorescence-activated
cell sorting (FACS) with a Becton-Dickinson FACScan. For each sam-
ple, at least 1 · 104 events were recorded.
2.5. Assay of H2O2
DU145 cells were serum-starved for 24 h. The cells were pretreated
with 5 lM of H2DCFDA for 5 min, followed by addition of IGF-1
(50 ng/ml). In 10 min, the cells were washed, ﬁxed, and checked under
ﬂuorescence microscope. To quantitate H2O2, DU145 cells were ser-
um-starved for 24 h. Cells were pre-incubated with H2DCF-DA
(5 lM) for 5 min at 37 C, then stimulated with IGF-I (50 ng/ml) for
10 min. The cells were harvested and resuspended in PBS. Fluores-
cence was monitored using a ﬂow cytometer (Becton-Dickinson FAC-
Sort). The mean of DCF ﬂuorescence intensity was obtained from
10,000 cells using 480-nm excitation and 540-nm emission settings.
After adding H2DCFDA, the samples were kept in the dark to avoid
light as much as possible.
2.6. Statistical analysis
The data represent mean ± SE from three independent experiments
except where indicated. Statistical analysis was performed by Student’s
t-test at a signiﬁcance level of P < 0.05.0%
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Fig. 1. IGF-1-induced proliferation of DU145 was inhibited by
LY294002 and PD98059. (A) Serum-starved DU145 cells (24 h) were
stimulated with IGF-1 for 15 min. (B) Serum-starved DU145 cells
(24 h) were pretreated by 20 lM of LY294002 or 50 lM of PD98059
for 30 min, followed by a stimulation with IGF-1 (50 ng/ml) for
15 min. (C) DU145 cells were serum-starved for 24 h. The cells were
pretreated with 20 lM of LY294002 or 50 lM of PD98059 for 30 min.
IGF-1 (50 ng/ml) was added and the cells were incubated for 24 h. The
cells were harvested for cell cycle assay.3. Results
3.1. Mitogenic eﬀects of IGF-1 on DU145 cells
IGF-1 stimulated phosphorylation of AKT and ERK in
DU145 cells (Fig. 1A). PI3K speciﬁc inhibitor LY294002
and ERK inhibitor PD98059 inhibited IGF-1-induced activa-
tion of AKT and ERK, respectively (Fig. 1B). LY294002
had no eﬀects on pERK and PD98509 had no eﬀects on
pAKT. Cell cycle analysis was determined as an index of cell
proliferation. Compared to control, IGF-1 increased cell num-
ber in S phase and decreased cell number in G1 phase, indicat-
ing the mitogenic eﬀects of IGF-1 (Fig. 1C). Both LY294002
and PD98059 inhibited IGF-1-induced the increase of cell
number in S phase and decrease of cell number in G1 phase
(Fig. 1C), suggesting that mitogenic eﬀects of IGF-1 were
through PI3K/AKT and MAPK/ ERK.3.2. IGF-1 activated ERK through EGFR
Next, we determined whether or not IGF-1 activated
ERK through EGFR. AG1478, the speciﬁc inhibitor of
EGFR, inhibited IGF-1-induced phosphorylaiton of EGFR
(Fig. 2A). The abrogation of EGFR activation led to inhibi-
tion of ERK1/2 (Fig. 2A). To exclude the possibility that
AG1478 inhibited EGFR through IGF-1R, we determined
the eﬀects of AG1478 on pIGF-1R under the same conditions.
As indicated, AG1478 had no eﬀects on IGF-1R phosphoryla-
tion (Fig. 2A). These results suggest that IGF-1 activates ERK
through EGFR.
3.3. IGF-1 transactivated EGFR via MMP-mediated release of
HB-EGF
Before stimulated with IGF-1, DU145 cells were preterated
with GM6001, an inhibitor of MMP. GM6001 suppressed
IGF-1-induced phosphorylation of EGFR (Fig. 2B), indicat-
ing that MMP is involved in this process. To conﬁrm that
the inhibitory eﬀect of GM6001 is a consequence of reducing
concentration of EGFR ligand and not of some unspeciﬁc
event, we added exogenous EGF. As shown in Fig. 2C, addi-
tion of exogenous EGF restored phosphorylation of EGFR
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Fig. 2. IGF-1 induces phosphorylation of EGFR via MMP-mediated
release of HB-EGF. (A) AG1478 inhibits IGF-1-stimulated phos-
phorylation of EGFR and ERK. Serum-starved DU145 cells
(24 h) were pretreated with AG1478 for 30 min. 50 ng/ml of IGF-1 was
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neutralizing antibody. DU145 cells were pretreated with anti-
HB-EGF neutralising antibody before stimulated with IGF-
1. Pretreatment of the cells with the antibody suppressed
IGF-1-stimulated phoshporylation of EGFR (Fig. 2D). Taken
together, these results suggest that IGF-1 activates EGFR
through shedding of HB-EGF in DU145 cells.
We have shown that inhibition of ERK suppressed the IGF-
1-induced cell proliferation (Fig. 1C) and activation of ERK is
dependent on EGFR transactivation (Fig. 2A). So, we next
determined the role of EGFR on IGF-1-induced cell prolifer-
ation. DU145 cells were pretreated with AG1478 or GM6001
and then stimulated with IGF-1. Both AG1478 and GM6001
inhibited IGF-1-induced cell proliferation (Fig. 2E), suggesting
that EGFR plays an important role in IGF-1-induced cell pro-
liferation in DU145 cells.
3.4. H2O2 is required for IGF-1-induced EGFR activation
H2O2, as a second messenger, plays an important physiolog-
ical role [15]. A few of growth factors and cytokines can induce
cellular formation of H2O2[16–21]. So, we want to exam
whether IGF-1 induces EGFR activation through H2O2. N-
acetyl-cysteine (NAC) and tiron were used in the test. NAC
is an oxidant that can reduce intracellular H2O2. Tiron, a
scavenger of superoxide, reduces formation of superoxide
and decreases H2O2 production. Both NAC and tiron blocked
IGF-1-induced activation of EGFR (Fig. 3A). To know that
NAC and tiron inhibit EGFR phosphorylation directly or
indirectly, we added EGF to the medium. Addition of exoge-
nous EGF rescued the phosphorylation of EGFR inhibited
by NAC or tiron (Fig. 3B), indicating that these antioxidants
did not target EGFR directly. In addition, NAC and tiron
had no eﬀects on phosphorylation of IGF-1R (Fig. 3C), sug-
gesting that these antioxidants aﬀected pEGFR not through
IGF-1R. We also tested with catalase. As shown in Fig. 3A,
addition of catalase inhibited pEGFR as well. The heat-inacti-
vated catalase had no eﬀects on pEGFR (Data not shown).
Taken together, our results suggest that H2O2 is required for
IGF-1-induced activation of EGFR.N 
added and the cells were incubated for 15 min. To detect phosphor-
ylation of IGF-1 R, immunoprecipitation was performed using anti-
body against IGF-1Rb. Phosphorylation of IGF-1R was determined
using antibody against phosphotyrosine (4G10) as described in Section
2. (B) The MMP speciﬁc inhibitor GM6001 abrogated IGF-1-induced
phosphorylation of EGFR. Serum-starved DU145 cells were pre-
treated with GM6001 for 30 min, followed by treatment with IGF-1
(50 ng/ml) for 15 min. (C) To detect whether or not EGF could rescue
pEGFR inhibited by GM6001, serum-starved DU145 cells were
pretreated with GM6001 for 30 min. The cells were stimulated with
IGF-1 (50 ng/ml) or IGF-1 plus EGF (20 ng/ml) for 15 min. (D) HB-
EGF neutralizing antibody blocked IGF-1-induced activation of
EGFR. Serum-starved DU145 cells were pretreated with HB-EGF
neutralizing antibody (3 lg/ml) for 30 min, followed by stimulation of
the cells with IGF-1 (50 ng/ml) for 15 min. (E) AG1478 and GM6001
inhibited IGF-1-induced DU145 cell proliferation. DU145 cells were
seeded onto 12-well plate at 1 · 105/well. The next day, the cells were
switched to serum-free medium and incubated overnight. The serum-
starved DU145 cells were pretreated with AG1478 or GM6001 for
30 min. IGF-1 (50 ng/ml) was added and the cells were incubated for
24 h. Then, the cells were trypsinized, harvested, and re-suspended in
PBS. Cell number was determined using haemacytometer under
microscope. Cell number of the well without any treatment is
designated as 100%. *P < 0.05 versus cells treated with IGF-1 alone.
Fig. 3. Basal H2O2 is required for IGF-1-induced activation of EGFR.
(A) NAC and Tiron inhibited IGF-1-induced activation of EGFR.
Serum-starved DU145 cells were pretreated with NAC (10 mM), tiron
(10 mM), or catalase (1500 u/ml) for 30 min. The cells were then
stimulated with IGF-1 (50 ng/ml) for 15 min. Density of each band was
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Fig. 4. IGF-1 did not induce formation of H2O2 in DU145 cells. (A)
DU145 cells were serum-starved for 24 h. The cells were pretreated
with 5 lM of H2DCFDA for 5 min, followed by addition of IGF-1. In
10 min, the cells were washed, ﬁxed, and checked under ﬂuorescence
microscope. (B) To quantitate H2O2, DU145 cells were serum-starved
for 24 h. Cells were pre-incubated with H2DCF-DA (5 lM) for 5 min
at 37 C, then stimulated with IGF-1 for 10 min. The cells were
harvested and resuspended in PBS. Fluorescence was monitored using
a ﬂow cytometer.
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EGFR phosphorylation in DU145 cells. To know this, we
stimulated the serum-starved DU145 cells with H2O2. Little in-
crease of EGFR phosphorylation could be observed (Fig. 3D).
In the meantime, we determined pIGF-1R under the same
conditions. As shown in Fig. 3D, the exogenous H2O2 didnot
aﬀect phosphorylation of IGF-1R, either. However, the exog-
enous H2O2 induced phosphorylation of AKT in DU145 cells
(Fig. 3D).
Next, we want to know whether IGF-1 stimulated formation
of H2O2 in DU145 cells. Results of H2DCFDA staining show
that IGF-1 did not increase the formation of H2O2 (Fig. 4A).
To conﬁrm this, we determined H2O2 production by ﬂowcy-
tometry method. In line with the results of Fig. 4A, IGF-1
did not induce H2O2 production (Fig. 4B). Addition of NACN 
measured. The relative intensity of pEGFR was calculated as the ratio
of pEGFR density/EFGR density. The intensity of pEGFR of control
is designated as 100%. The data are mean ± S.D. from three
independent experiments. , P < 0.05 versus IGF-1 alone. Cat,
catalase. (B) To determine whether or not EGF could rescue pEGFR
inhibited by NAC or tiron, serum-starved DU145 cells were pretreated
with NAC (10 mM) or tiron (10 mM) for 30 min. The cells were then
stimulated with IGF-1 (50 ng/ml) or IGF-1 plus EGF (20 ng/ml) for
15 min. (C) NAC and tiron did not inhibit phosphorylation of IGF-
1R. DU145 cells were treated as described in (A) and immunoprecip-
itation was performed using antibody against IGF-1Rb. Phosphor-
ylation of IGF-1R was determined using antibody against
phosphotyrosine (4G10). (D) Exogenous H2O2 did not induce phos-
phorylation of EGFR and IGF-1R. Serum-starved DU145 cells were
treated with H2O2 for 10 min. Cells were harvested for immunoblot-
ting and immunoprecipitation as described above.
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suggest that IGF-1 does not induce EGFR activation through
stimulation of H2O2 production.4. Discussion
Insulin-like growth factors are potent mitogens and survival
factors for a variety of cancers including prostate cancer since
they stimulate cancer cells proliferation and suppress apopto-
sis. These eﬀects are mediated primarily through the IGF-1R
[22]. It is established that IGF-1-activated IGF-IR relays the
IGF signal to the two pathways via diﬀerent docking mole-
cules: it is linked to the PI3K by IRS-I, to the MAPK/ERK
pathway via Shc, Grab2 and Sos [23]. It was also found in a
few of cell types that IGF-1 activates MAPK/ERK through
EGFR [7–11,13]. The mechanisms that IGF-1 induces activa-
tion of ERK remain largely unknown. In some cells, IGF-1
activates ERK via MMP-mediated shedding of HB-EGF
[9,13]. But in other cells, it is not [10]. The conﬂicting results
suggest EGFR transactivation makes a variable contribution
to IGF-1R-mediated ERK activation in diﬀerent cells.
In DU145 cells, we found that IGF-1 activates ERK
through activation of EGFR that is mediated by shedding of
HB-EGF (Fig. 2). H2O2, as a second messenger, activates a
few signal cascades and plays an important physiological roles
[15]. So, we asked whether H2O2 is involved in IGF-1-induced
EGFR activation in DU145 cells. NAC and tiron inhibited
IGF-1-indued pEGFR (Fig. 3A), which was rescued by exog-
enous EGF (Fig. 3B). These results suggest that NAC and tir-
on do not target EGFR directly. We also found that NAC and
tiron had no eﬀects on IGF-1-induced phosphorylation of
IGF-1R (Fig. 3C), indicating that NAC and tiron inhibits
EGFR activation not through IGF-1R. Moreover, addition
of catalase also suppressed IGF-1-induced activation of
EGFR (Fig. 3A). Although catalase cannot enter into the cell,
cell membrane is H2O2 permeable. So, treatment of the cells
with catalase will reduce the intracellular level of H2O2. The
inhibitory eﬀect of catalase is not as strong as those of NAC
and tiron. This is probably due to free entry of these antioxi-
dants to cells. These results suggest that H2O2 is required for
EGFR activation by IGF-1.
Previous reports demonstrated that exogenous H2O2 trans-
activated EGFR [24–26]. In our laboratory, we also found that
exogenous H2O2 could induce phosphorylation of EGFR in
rat vascular smooth muscle cells (Data not shown). To our sur-
prise, the exogenous H2O2 could not induce EGFR phosphor-
ylation in DU145 cells (Fig. 3D). Addition of H2O2 could not
induce IGF-1R phosphorylation, either (Fig. 3D). These re-
sults suggest that, in DU145 cells, H2O2 is required but not en-
ough to activate EGFR.
We found that H2O2 was required for IGF-1 to activate
EGFR and IGF-1 did not induce production of H2O2 in
DU145 cells. These results suggest that the basal intracellular
H2O2 plays an important role in this process. Exogenous
H2O2 did not activate either EGFR or IGF-1R (Fig. 3D). It
will be interesting to know the mechanisms that H2O2 aﬀecting
IGF-1-induced EGFR signaling. Because EGF reversed the
inhibitory eﬀects of NAC and tiron on EGFR (Fig. 3B), one
possibility is that H2O2 is required for shedding of HB-EGF,
which remains to be elucidated in future work.IGF-1/IGF-1R system plays an important role in prostate
cancer cells proliferation and tumor growth. The mitogenic
eﬀects of IGF-1 require EGFR transactivation in prostate
cancer cells. Blockade of IGF-1-induced transactivation of
EGFR abrogates cell proliferation. Here we demonstrated
for the ﬁst time that cell basal H2O2 is required for IGF-1 to
transactivate EGFR in DU145 cells. Our results provide new
insight on the mechanisms of transactivation of EGFR/ERK
by IGF-1. The mechanism how basal hydrogen peroxide mod-
ulates the ability of IGF1 to transactivate the EGFR is under
investigation in our lab.
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